Abstract
Primary and secondary structures of mammalian mitochondrial (mt) tRNAs are divergent from canonical tRNA structures due to highly skewed nucleotide content and large size variability of D- and T-loops. The nonconservation of nucleotides involved in the expected network of tertiary interactions calls into question the rules governing a functional L-shaped three-dimensional (3D) structure. Here, we report the solution structure of human mt-tRNAAsp in its native post-transcriptionally modified form and as an in vitro transcript. Probing performed with nuclease S1, ribonuclease V1, dimethylsulfate, diethylpyrocarbonate and lead, revealed several secondary structures for the in vitro transcribed mt-tRNAAsp including predominantly the cloverleaf. On the contrary, the native tRNAAsp folds into a single cloverleaf structure, highlighting the contribution of the four newly identified post-transcriptional modifications to correct folding. Reactivities of nucleotides and phosphodiester bonds in the native tRNA favor existence of a full set of six classical tertiary interactions between the D-domain and the variable region, forming the core of the 3D structure. Reactivities of D- and T-loop nucleotides support an absence of interactions between these domains. According to multiple sequence alignments and search for conservation of Leontis–Westhof interactions, the tertiary network core building rules apply to all tRNAAsp from mammalian mitochondria.
INTRODUCTION
Transfer RNAs (tRNAs) constitute key molecules in protein biosynthesis in all living organisms. To fulfill their biological role, they have specific structural properties allowing interactions with several partners such as their cognate aminoacyl-tRNA synthetases (aaRSs), elongation factor, mRNA or ribosome (1). Presently, several thousands of tRNA sequences are known (2). A vast majority of them fold into the canonical cloverleaf secondary structure, and furthermore into a three-dimensional (3D) functional L-shape as first revealed by the crystal structure of tRNAPhe (3,4). Transition from 2D to 3D structure is supported by nine tertiary interactions involving conserved and semi-conserved residues that are localized within the D- and the T-loops, and within the core of the molecule (connector regions, D-stem and variable region). The tertiary interaction network is conserved in bacterial, archaeal and eukaryal cytosolic tRNAs. It involves nucleotides which either form atypical base-pairs or triple interactions, the latter made either of three remote nucleotides or of a Watson–Crick pair and an additional distant nucleotide (5,6).
A major unanswered question, however, concerns the 3D folding rules for mammalian mitochondrial tRNAs (mt-tRNAs) for which sequences are not canonical. Sequence comparison of these tRNAs, in addition to the description of typical characteristics of secondary structures, highlighted ‘bizarre’ features (7). Exceptionally of tRNASer(AGY) is missing the full D-domain and tRNASer(UCN) has an extended anticodon stem. Mammalian mt-tRNAs present other unprecedented size variations in both D- and T-loops and lack a number of conserved and semi-conserved residues essential to the establishment of a canonical tertiary interaction network. Only four families (tRNALeu(UUR), tRNALeu(CUN), tRNAGln and tRNAAsn) show strong conservation of the nine potential classical tertiary interactions, including those between the D- and T-loops, and may thus well fold into the canonical L-fold (7). For all other families, a gradual disappearance of the theoretical tertiary interactions is observed; in extreme examples only three of them can be predicted (7). A few mammalian mt-tRNAs have been investigated experimentally for their 3D structural features. Two atypical tRNASer(UCN) (8,9) and tRNASer(AGY) (10) have been studied by enzymatic and chemical structure probing in solution, and a nuclear magnetic resonance (NMR) structure was established for tRNASer(AGY) (missing the D-domain) (10). Transient electric birefringence experiments showed that the angle between the two branches of the ‘L’ is more obtuse for these two tRNAs and for human mt-tRNALys than for classical tRNAs (120°–140° as compared to 70°–90° respectively) (11,12). In the single case of bovine mt-tRNAPhe, solution mapping experiments with enzymatic and chemical probes lead to 3D structural information on a moderately diverging ‘bizarre’ mt-tRNA (13). In this tRNA, the presence of the six expected tertiary interactions within the core of the tRNA is supported experimentally and the absence of conserved nucleotides G18G19 and T54ΨCG57 in the D- and T-loops, respectively, leads to the absence of interaction between the corresponding domains at the corner of the expected ‘L’ fold.
For a refined understanding of the rules that govern the folding of mammalian mt-tRNAs, we have tackled the case of human mt-tRNAAsp by structural mapping in solution with enzymatic and chemical probes. This tRNA has already been investigated to determine the identity signals responsible for specific aspartylation by human mt-AspRS (14). The number of such signals is severely reduced in comparison with tRNAAsp from other kingdoms: only two important elements in the anticodon triplet are maintained and the discriminator nucleotide G73 is lost, suggesting a strongly degenerated set of identity elements in mammalian mt aspartylation systems (14). This observation prompted us to search for concomitant structural alteration of the tRNA, in order to gain some insight into structure/function evolution of aminoacylation systems in mitochondria. Experiments were performed on both native tRNA extracted from HeLa cells and human placenta, containing all the post-transcriptional modifications, as well as on the corresponding in vitro transcript.
Here, the set of post-transcriptional modifications of native human mt-tRNAAsp has been defined and a cloverleaf retrieved as secondary structure. However, a combination of three alternate secondary structures, including a cloverleaf, a cloverleaf with a large loop and an extended bulged hairpin, has been discovered for the in vitro transcribed RNA, demonstrating the high contribution of post-transcriptional modifications to structure the mt-tRNAs. Reactivities in native tRNA toward structural probes are in favor (i) of the existence of an extensive tertiary network of interactions forming the core of an L-shaped structure and (ii) of the absence of interactions between the D- and T-loops. The relevance of the rules governing the tertiary network of human mt-tRNAAsp applied to other mammalian mt-tRNAs is discussed in terms of conservation of Leontis–Westhof interaction patterns in the six core tertiary interactions.
MATERIALS AND METHODS
Materials
Diethylpyrocarbonate (DEPC), aniline, hydrazine, TRI REAGANT®, 5′-biotinylated oligonucleotide and streptavidin-coated beads were purchased from Sigma-Aldrich. Nuclease T1 used for enzymatic structure probing was from Stratagene, nuclease S1 as well as ribonuclease V1 were from PIERCE. Dimethylsulfate (DMS) was bought from Acros Organics. RNase T1 used for mass spectrometric analyses was purchased from EPICENTRE Biotechnologies. Acrylonitrile was purchased from Wako Pure Chemical Industries. [γ-32P]ATP (3000 Ci/mmol) was from Amersham.
Mass spectrometric analysis of the post-transcriptional modifications in human mt-tRNAAsp
Mt-tRNAAsp purified from human placenta as described previously (15,16) was provided by Dr. Yohei Kirino (Univ. of Pennsylvania). The sequence of a synthetic 3′-biotinylated DNA for the chaplet column chromatography was 5′-taagatatataggatttagcctataattta-3′. The purified tRNAAsp (250 fmol) was digested by RNase T1 or RNase A, and then analyzed by capillary liquid chromatography (LC)/nano electrospray ionization mass spectrometry (nanoESI-MS) as described (17). A linear ion trap-orbitrap hybrid mass spectrometer (LTQ Orbitrap XL, Thermo Fisher Scientific) was equipped with a custom-made nanospray ion source and a splitless nano HPLC system (DiNa, KYA Technologies). Cyanoethylation was carried out according to the literature (18) with slight modifications. Reaction mixture (16 µl) consisting of 1 µl of 1 µM tRNAAsp, 13 µl of 1.1 M triethylammonium acetate (pH 7.0) with 41% ethanol and 2 µl of acrylonitrile was incubated at 70°C for 2 hours. After cyanoethylation, the mixture was lyophilized and dissolved with water. Half the amount was digested by RNase T1, then subjected to the LC/nanoESI-MS analysis.
Structural mapping in solution
Native tRNA was prepared from HeLa cell mitochondria according to established procedures. Total mitochondrial tRNAs were extracted by using the TRI REAGANT® method following the manufacturer’s procedure. Specific mitochondrial tRNAAsp was isolated from total tRNAs as previously described in (19,20) by hybridization to a 5′-biotinylated oligonucleotide bound to streptavidin coated beads and complementary to 34 nt at the 5′-end of the tRNA. The gene for human mt-tRNAAsp has been cloned previously (21) including a hammerhead ribozyme (22) and tRNA sequence downstream of the T7 polymerase promoter. A BstNI site was inserted coincidental with the 3′-end of the tRNA sequence, which allows the synthesis of tRNA ending with the expected CCA sequence. In vitro transcription was performed as described in (21) with adequate amounts of T7 RNA polymerase (purified according to ref. 23). After phenol extraction, the transcript was purified on denaturing 12% polyacrylamide/8 M urea gels, electroeluted and ethanol-precipitated.
Structural mapping of tRNAs was done using enzymatic (nuclease S1, specific for single-stranded region and ribonuclease V1, specific for duplex or highly structured region) and chemical (DMS, specific for N3 of cytosine, DEPC, specific for N7 of adenosine, and lead (Pb2+), specific for single-stranded regions) probes. [32P]-labeling of the tRNA transcript 5′-end and the subsequent purification of tRNA molecules from polyacrylamide gels were carried out as described earlier (24). Before structural probing, transcripts were denatured by heating at 60°C in H2O and slowly cooled down to room temperature.
Enzymatic probing
Digestion with nuclease S1 or ribonuclease V1 were performed as described (24). Briefly, transcripts were incubated in 50 mM HEPES-KOH pH 7.5, 10 mM MgCl2 and 25 mM KCl for 5 min at 25°C. For digestion with S1 nuclease, 1 mM ZnCl2 was added. Reaction mixtures (10 µl) contained 30 000 Cerenkov c.p.m. of transcript supplemented with 2 µg of unlabeled Escherichia coli total tRNA and either 12.8 U nuclease S1 or 3.6.10–2 U RNase V1. Cleavage reactions were performed during 5 min at 25°C and were stopped by adding 1 vol of 0.6 M AcONa pH 5, 3 mM EDTA and 0.1 mg/ml E. coli total tRNA followed by ethanol precipitation.
Chemical probing
Modification of N7 atoms of guanosine residues and of N3 atoms of cytosine residues by DMS, and modification of N7 positions of adenosine by DEPC were done according to established procedures (25). Optimal concentration of chemicals and incubation times for mt-tRNA transcripts were chosen as described (24). Under native conditions, DMS reactions were for 10 min at 25°C in 50 mM HEPES-NaOH pH 7.5, 5 mM Mg(OAc)2, 50 mM K(OAc) and 2 mM β-mercaptoethanol. Semi-denaturing conditions were for 5 min at 25°C in 50 mM HEPES-NaOH pH 7.5, 50 mM K(OAc), 1 mM EDTA and 2 mM β-mercaptoethanol. Denaturing conditions were for 30 s at 60°C in 50 mM HEPES-NaOH pH 7.5 and 1 mM EDTA. DEPC modification was as with DMS but incubation times were 10 and 20 min for native and semi-denaturing conditions and 5 s for the denaturing one. Cleavage reactions were performed for 10 min in the dark at 60°C using 10 µl of a modified aniline solution (100 µl 1 M aniline, 60 µl CH3COOH and 930 µl H2O). Concerning the DMS, the cleavage reaction was preceded by a second modification using 10 µl hydrazine 50% (v/v in water) for 5 min in the dark. Between all the modification and the cleavage steps, tRNAs were ethanol precipitated. All cleavage products were analyzed on denaturing polyacrylamide gels as described below.
Cleavage by Pb(OAc)2 was performed as described in (26). Briefly, transcripts were incubated in 50 mM HEPES-NaOH pH 7.5, 5 mM Mg(OAc)2 and 50 mM K(OAc) for 10 min at 25°C. A freshly prepared Pb(OAc)2 solution in water was added to final concentrations of 5 and 25 mM. Samples (10 µl) were incubated at 25°C for 5 min. Reactions were stopped by cooling on ice, adding EDTA to a final concentration of 33 mM and ethanol precipitated. Control without probe was run in parallel.
Assignment of cleavage positions
Alkaline ladders were performed by incubation of labeled transcripts (30 000 Cerenkov c.p.m.) and 2 µg of total tRNA from E. coli in 50 mM NaHCO3 pH 9, at 80°C for 8 min. Guanine ladders were obtained by incubation of labeled transcripts in 10 mM Na-citrate pH 4.5, 3.2 M urea, 0.4 mM EDTA and 2 µg of unlabeled E. coli total tRNA for 4 min at 60°C followed by the addition of 2 U RNase T1 and a second incubation at 60°C for 4 min. The products of the probing reactions were analyzed on 12% polyacrylamide/8 M urea denaturing gels. Controls without probes but supplemented with ZnCl2 were run in parallel on each gel.
Mt-tRNAAsp 3D modeling
A 3D model of human mt-tRNAAsp was built on the basis of the crystallographic structure of E. coli tRNAAsp in complex with AspRS (PDB id: 1C0A) (27). Sequence changes as well as base and phospho-ribose backbone manipulations were performed with ‘O’ (28) and ‘assemble’ (http://www.bioinformatics.org/assemble/ -ref. 29), and conjugate-gradient minimization (500 cycles in restrained Cartesian mode) of the model (including hydrogen atoms) was performed with CNS (30). Figures of the 3D model were prepared with PyMol (31).
RESULTS
Background
Figure 1A recalls nucleotides involved in the network of tertiary interactions sustaining classical tRNA 3D structures (tRNAs from bacteria, archae, eukaryotic cystosol; ref. 5,6). Nine interactions are present. Most of the network takes place in the core of the molecule, namely in the D-arm and the variable region, involving nucleotides which either form a pair at long-distance (i.e. R15-Y48, N26-N44 with R for purine, Y for pyrimidine, N for any nucleotide), or which form triples. Triples involve either a base pair formed along the secondary structure and a single nucleotide at distance (i.e. 9/12-23, 13-22/46, 45/10-25), or 3 nt unrelated in the secondary structure (i.e. U8-A14-A21). Three further interactions involve the T- and D-loops, one interaction within the T-loop (T54-A58) and two interactions bringing the two loops close to each other (G18-Ψ55, G19-C56), to form the elbow of the ‘L’. Mammalian mt-tRNAAsp (Figure 1B) deviate from canonical tRNAs by sizes of D- and T-loops and by the lack of several conserved and semi-conserved residues essential to the establishment of the tertiary interaction network. Strategic nucleotides, especially nucleotides G18 and G19 in the D-loop, and nucleotides U54U55C56 of the T-loop are absent, leaving the question open of the existence of any interaction between these loops. By analogy to classical tRNAs, only four potential tertiary interactions in the core of the 3D structure would be conserved when the full set of available mammalian mitochondria sequences of tRNAAsp are considered (7,32) (Figure 1B). Among them, the existence of the triple interaction A9/A12-U23 has recently been experimentally confirmed while investigating the effects of myopathy-related mutation A7526G (A9G) on structure and aminoacylation properties of mt-tRNAAsp (33).
Post-transcriptional modifications in human mt-tRNAAsp
Native mt-tRNAAsp (Figure 2A) was isolated from human placenta by the chaplet column chromatography (15,16). To determine species and positions of the post-transcriptional modifications, human mt-tRNAAsp was digested by RNase T1 or RNase A into fragments, and analyzed by a highly accurate and sensitive method of RNA mass spectrometry (capillary LC/nanoESI-MS) (17). As shown in Figure 2B and Table 1, we could detect negatively-charged ions of 15 digestion fragments produced by RNase T1 and RNase A digestions that cover the whole sequence of mt-tRNAAsp. According to the observed values of singly or multiply charged ions, the exact molecular masses of the RNA fragments with or without modifications could be unambiguously determined (Table 1). Each fragment was further analyzed by a MS/MS experiment using collision-induced dissociation (CID) to position the detected modifications in the tRNA sequence. The MS/MS analysis of fragment No. 4 (Table 1) determined 1-methyladenosine (m1A) at position 9 and N2-methylguanosine (m2G) at position 10 (Figure 2C). These two modifications are conserved at the corresponding positions in several animal mt-tRNAs (tRNAdb, (2), http://trnadb.bioinf.uni-leipzig.de/). We also found m2G at position 10 occurred partially as observed in the CID spectrum of fragment No. 4′ (UAUUm1AGp) (Figure 2C). Judging from the peak area in the mass chromatogram, about 50 % of G10 is modified to m2G10 (Figure 2B). The anticodon-containing fragment (No. 1) showed a molecular mass of 27-mer RNA containing a wobble modification of queuosine (Q). As it is known that Q is a modified G that is resistant to RNase T1 digestion (34), Q can be assigned at position 34 in principle. We also observed partial modification of Q34 (∼10%), resulting in the detection of the 21-mer RNA (No. 1′) which was cleaved at position 34 by RNase T1 (Figure 2B and Table 1). For detecting mass-silent pseudouridine (Ψ), Ψ in tRNAAsp was cyanoethylated by acrylonitril treatment, prior to RNase T1 digestion. We found the fragment No 1′ increased in molecular mass by 53 Da, indicating a single Ψ to be present in this fragment. In the CID spectrum of the cyanoethylated RNA fragments No. 1′ (Figure 2D), the quadruply charged product ion w8′ (m/z 669.8212) exactly matched with the m/z value containing cyanoethylated-Ψ. On the contrary, in the CID spectrum of nonderivatized No. 1′ (Figure 2D), we detected the related product ion w8 (m/z 656.5684) which corresponds to the unmodified RNA fragment. Besides, other product ions of 3′-termini including y1, y3, w4 and w5 are commonly found in both CID spectra. These data demonstrate that Ψ was placed at position 27. In summary, human mt-tRNAAsp has Ψ27, m1A9, m2G10 and Q34 as its post-transcriptional modifications (Figure 2A).
Table 1.
No | Sequences of RNA fragments | Molecular mass | Monoisotopic m/z |
Charge state | |
---|---|---|---|---|---|
Observed | Calculated | ||||
RNase T1 fragments | |||||
1 | AAAAACCAUUUCAΨAACUUUQUCAAAGp | 8756.213 | 795.0098 | 795.012 | −11 |
1′ | AAAAACCAUUUCAΨAACUUUGp | 6686.873 | 741.9777 | 741.978 | −9 |
2 | CUAAAUCCUAUAUAUCUUACCA (3′ terminus) | 6848.915 | 683.9017 | 683.884 | −10 |
3 | UUAAAUUAUAGp | 3538.447 | 706.6801 | 706.682 | −5 |
4 | UAUUm1Am2Gp | 1967.270 | 982.6292 | 982.627 | −2 |
4′ | UAUUm1Agp | 1953.255 | 975.6188 | 975.619 | −2 |
5 | pAAGp (5′ terminus) | 1101.129 | 1100.1222 | 1100.122 | −1 |
RNase A fragments | |||||
6 | m1Am2GAAAAACp | 2670.446 | 1334.2153 | 1334.215 | −2 |
7 | pAAGGUp (5′ terminus) | 1752.202 | 875.0916 | 875.093 | −2 |
8 | AAAGUp | 1656.241 | 827.1147 | 827.113 | −2 |
9 | AGGCp | 1342.199 | 670.0933 | 670.092 | −2 |
10 | AAAUp | 1311.193 | 654.5911 | 654.589 | −2 |
11 | AACp | 981.157 | 980.1503 | 980.149 | −1 |
12 | AUp or AΨp | 653.088 | 652.0830 | 652.081 | −1 |
13 | ACp | 652.104 | 651.0989 | 651.097 | −1 |
Enzymatic and chemical solution structure of native human mitochondrial tRNAAsp
Structure probing in solution is based upon the reactivity of RNA molecules toward chemicals or enzymes that have a specific target on RNA (35–37). Probes are used under statistical conditions where less than one cleavage or modification occurs per molecule. In the present work, accessibility of the human mt-tRNAAsp has been probed under native conditions by nucleases specific for single-stranded (nuclease S1) and double-stranded or structured regions (ribonuclease V1). While the use of these enzymatic probes allows deciphering of the overall secondary structure of the RNA, a more precise investigation at the atomic level involves the chemical probes DMS, DEPC and Pb2+. DEPC modification at N7 position of adenine residues and DMS modification at N3 position of cytosine residues can be detected by strand scission with aniline. If these atoms are accessible and reactive in the RNA 3D structure, they are detected under native conditions. If they are involved in secondary or tertiary structural elements, they are non-reactive under native conditions but become detectable under semi-denaturing and fully denaturing conditions.
Probing experiments have been performed at 25°C on 5′- or 3′-end labeled tRNA molecules. Cleavage fragments were revealed on denaturating 12% polyacrylamide gels. Representative autoradiograms of enzymatic cleavage of native tRNAAsp (with post-transcriptional modifications) are presented in Figure 3A. Complete data resulting from extensive probing with both enzymatic and chemical probes are summarized on a cloverleaf structure (Figure 3B). Control incubations without probes confirmed the intrinsic weakness of human mt-tRNAs at pyrimidine-A bonds as already described for tRNALys (24) and tRNALeu(UUR) (38). All degradations are annotated on the autoradiograms as well as on the cloverleaf structure. For technical reasons, residues 1–10 and 74–76 could not be investigated.
Analysis of nucleotide reactivities to chemical probes and of phosphodiester bonds to enzymatic probes within native tRNAAsp unambiguously reveals a classical cloverleaf. Typical reactivities correspond to strong cleavages by single-strand specific nuclease S1 all along residues 14–20 (corresponding to the D-loop), residues 32–35 (anticodon loop), residues 44 and 45 (variable region) and residues 55 and 56 (T-loop), as well as cleavages by the double-strand specific ribonuclease V1 all along nucleotides 28, 29 (anticodon stem), 43 (end of anticodon stem/entry of variable region), nucleotides 62–65 (T-arm) and nucleotides 69, 70 and 72 (acceptor arm). Significant alkylation by DMS under native conditions, as revealed by direct strand scission, is observed at the N3 position of residues C16 and C20 (D-loop), C36 (anticodon loop) and C54 (T-loop), whereas residues C26 (D-arm), C30 (anticodon arm) and C61 and C62 (T-arm) are not reactive under native conditions (not shown). These residues become fully reactive under denaturing conditions. Reactivities of adenosines to DEPC under native conditions are strong for residues A21 (D-loop), A37 and A38 (anticodon loop) and A56 and A57 (T-loop), while residues A11–A13 (D-arm), A28 and A29 (anticodon arm) and A49, A51 and A64 (T-arm) are not reactive. However, some reactivities do not fit. The phosphodiester bond 5′ to nucleotide C20 (D-loop) is cut by ribonuclease V1.
Unfortunately, the corresponding cleavage product co-migrates with the product of degradation between residues C20 and A21, therefore no conclusion about the involvement of residue C20 within a tertiary interaction can be proposed. Moreover, residues A12 and A13 (D-arm) are reactive towards the single-strand specific nuclease S1.
Nucleotides within D- and T-loops deserve particular attention. In the D-loop, all phosphodiester bonds are cleaved by single-strand specific enzymatic probe, two major degradations occur, and atomic positions of bases are reactive to chemical probes. Accordingly, the possibility of interaction of this loop with another domain of the RNA is restrained. T-loop nucleotides are also very reactive to both single-strand specific enzyme and to chemical probes. Further, degradation at U55/A56 is strong. Accordingly, the T-loop nucleotides are not protected against structural probes by any neighboring RNA domain. Nonreactivity of several atomic positions to chemical probes can be interpreted by intrinsic folding of either loop. N7 of A58 is likely to reflect a stacking with neighboring nucleotides C54 and/or U55. The present data are not in support of D- and T-loop interactions. The absence of reactivity of N7 A14 fits with an interaction with residue U8 through a Hoogsteen interaction as in classical tRNAs (6). Reactivity of N7 A21 to DEPC under native conditions is in agreement with interaction of residues A14 and A21 in a way not involving the Hoogsteen side.
The D-stem and variable region of mt-tRNAAsp are rich in adenosine residues. None of these adenosines (A11–A14, and A44–A46) is reactive to DEPC under native conditions. Accordingly, their N7 atoms are involved in a higher-order structure. They can be protected against DEPC either due to stacking with neighboring bases and/or due to hydrogen bonding within tertiary interactions. Nonreactivity of N7 A45 supports an involvement in the triple interaction G10-C25/A45 and non-reactivity of N7 A46 with an involvement in the triple A13-U22/A46. Nonreactivity of N7 of A26 and A44 is in agreement with their involvement in stacking.
Enzymatic and chemical solution structure of in vitro transcribed human mitochondrial tRNAAsp
Probing experiments on in vitro transcribed mt-tRNAAsp have been performed using the same enzymatic and chemical probes as for native tRNA, under similar conditions. In addition, reactivity to Pb2+ has been investigated. Representative autoradiograms and the full set of reactivities under native conditions are summarized on the theoretical cloverleaf structure (Figure 4A1 and A2). Control incubations without probes confirmed the intrinsic higher sensitivity of the transcript as compared to native tRNA extracted from human cells, at pyrimidine-A bonds (as already described in 24,38). These degradations are annotated along the autoradiograms as well as localized on the cloverleaf structure. As was the case for the native tRNA, reactivities of residues 1–9 and 74–76 could not be observed.
Comparing the cleavage pattern of this molecule to native tRNAAsp, the same reactivities of residues A28 to C30, U32 to U41 and C61 to A73 towards enzymatic (nuclease S1 and ribonuclease V1) and chemical probes (DMS and DEPC) can be observed and are therefore compatible with a secondary cloverleaf structure. Reactivity of the variable region nucleotides to chemical probing (N7 of A44 and A45 are reactive to DEPC and A44 to U47 are sensitive to the Pb2+) is also consistent with this secondary structure. However, the other nucleotides display a mixture of opposite reactivities. Thus, the D-arm can be either be structured or open. A11 to A13 and U22 to U24 are cut by the double-strand specific ribonuclease V1 but also by the single-strand specific nuclease S1 and are sensitive to the lead probe. It should also be noticed that residues G10 and C25 are also cleaved by the two latter probes. Along the same trend, N7 atoms of residues A11 to A13 are reactive to DEPC. Two incompatible cleavage patterns within the theoretical D-loop are also observed. While N7 of adenosine and N3 of cytosine are reactive toward single-strand specific probes, nucleotides A14–A21 are reactive to Pb2+ and nucleotide A14 to nuclease S1, ribonuclease V1 cuts can be observed for all the nucleotides belonging to the loop (A14–A21). Two residues of the anticodon arm (U42 and A43) are reactive not only to RNase V1 (in agreement with the presence of an arm) but also to Pb2+. In addition, N7 of A43 is reactive to DEPC. Contradictions of these types are also observed in the T-arm. On one the one hand, nucleotides A49–A51 and C62–A64 are cleaved by ribonuclease V1 and N7 atoms of residues A49 and A64 as well as N3 atoms of residues C61 and C62 are not reactive toward chemical probes. On the other hand, A49 and U50 are sensitive to nuclease S1 and N7 of A51 is reactive to DEPC. Finally, reactivities of the N3 of C53 as well as the N7 of A55 and A56 toward the chemical probes, C53–A55 toward the Pb2+ and A55 and A56 toward the nuclease S1 are in agreement with the presence of a T-loop. Reactivity of N7 position of residue A58 to DEPC under semi-denaturing conditions and discrete cleavage by ribonuclease V1 of A55 are in agreement with an internal loop interaction (between A58 and C54). Considering all these data, it can be concluded that the in vitro transcribed mt-tRNAAsp mainly folds into a secondary cloverleaf structure but alternative structures are also present. Figure 4B presents two possible alternative folds to the cloverleaf, namely a cloverleaf with an open D-domain and an extended hairpin structure.
Database analysis
A set of 136 mammalian mt-tRNAAsp sequences is available in the specific mammalian mt-tRNA database Mamit-tRNA (32). Figure 1B shows the most typical combination of nucleotides present in this group of molecules. A large variability in D- and T-loop size is observed. A more detailed analysis reveals three main types of D-loop sequences (5′-AAA-3′; 5′-AAYYA-3′; 5′-AAYAA-3′) (Y for pyrimidines) and three main types of T-loop sequences (5′-TGAAAAT-3′; 5′-TYAAAYY-3′; 5′-TTTAAAT-3′). Whatever the combination of the facing loops, no obvious Watson–Crick interaction can be drawn. Structural weaknesses of D-/T-loops interaction are not likely to be compensated within the tRNA itself, in contrast to various internal compensations observed in a number of highly bizarre tRNAs from animal mitochondria (39–41).
With regard to core interactions, the existence of four out of the six tertiary interactions appears possible, with most typical sequences A26–R44, G10–Y25/R45; A12–U23/A9; A13–U22/Y46. Considering a more detailed analysis of these core interactions within mt-tRNAAsp families in different mammalian super-order/orders allows a fine tuned view (Supplementary Data). In all families, conservation of nucleotides is highly significant, although not absolute. This is in support of a strong contribution of tertiary interactions within the core to drive the folding of mammalian mt-tRNAAsp. To search in a finer way for conservation of tertiary interactions, the set of the six candidate interactions in the core has been analyzed according to the Leontis–Westhof rules of nucleotide interactions (42). These rules propose a classification and nomenclature of nucleoside interactions found in crystal structures, according to the ‘edges’ participating in the interaction and to the orientation of the glycosidic bonds relative to the hydrogen bonds. This format allows identification of pairs that co-vary or interchange in sequence between homologous molecules while maintaining the 3D topology. Table 2 summarizes the six core interaction schemes (involving 16 nt) in the 136 mammalian mt-tRNAAsp sequences and their comparison to interaction patterns found in classical tRNAs. As an outcome, 98.3% of interactions are strictly conserved, in strong support for the existence of the full set of classical tertiary interactions in the core of mammalian mt-tRNAAsp. These interactions in the core domain are depicted in the Supplementary Data.
Table 2.
DISCUSSION
In vitro transcribed mt-tRNAAsp folds into a variety of secondary structures
Enzymatic and chemical probing of the in vitro transcribed human mt-tRNAAsp reflects the existence of alternative structures. In addition to the dominant classical cloverleaf, large nucleotide stretches cleaved by nuclease S1 or by lead, and with reactivity to chemical probes under native conditions suggest a version with an unstructured D-domain. A further fold corresponds to an extended hairpin. In comparison to the initial cloverleaf, this structure maintains the 7 bp of the acceptor stem and part of the anticodon domain. On the contrary, the D- and T-domains are totally refolded with numerous interdomain base pairs. The existence of alternate structures of in vitro transcripts has already been observed for other human mt-tRNAs (43,44). This situation was first characterized for tRNALys that does not adopt a cloverleaf but two alternative extended hairpins. In this case, the occurrence of a cloverleaf requires the presence of modified nucleotides (24,45). A single methyl group at position 9 (m1A9) is of major importance in this process since it hinders base pairing of nucleotide 9 with nucleotide 64 in the T-stem (this can also be achieved by mutating A9 to C, or U64 to A or C). All these variants show cloverleaf-type probing patterns and are aminoacylated by human lysyl-tRNA synthetase while the wild-type transcript is not (45,46). Single-molecule FRET analysis revealed that the wild-type in vitro transcribed mt-tRNALys exists in a conformational equilibrium between cloverleaf and hairpin structures and that methylation of residue A9 controls this equilibrium in favor of an active cloverleaf (47,48). Enzymatic and chemical probing experiments conducted on in vitro transcribed tRNAIle (49) and tRNALeu(UUR) (38,50,51) confirmed the folding of these molecules into a secondary cloverleaf structure but further showed that they could additionally adopt alternative structures such as a cloverleaf with open D- and anticodon stems for the tRNALeu(UUR) (38). The corresponding ‘floppy’ tertiary structure of the anticodon arm in the expected L-shaped tRNALeu(UUR) becomes converted into a functional tRNA upon interaction with the cognate aminoacyl-tRNA synthetase (52). In vitro transcribed tRNATyr however, preferentially folds into the cloverleaf (26). This is in-line with the ranking of human mt-tRNAs into two families according to the DNA-strand on which they are encoded, both strands being highly skewed in nucleotide composition (53). tRNATyr is a G-rich, ‘heavy’, human mt-tRNA and consequently folds into a more stable structure than the highly A-, U- and C-rich ‘light’ tRNAs including the aforementioned tRNALys, tRNAIle and tRNALeu(UUR) (7). The present data on human mt-tRNAAsp solution structures are a new example demonstrating the intrinsic structural plasticity of ‘light’ mt-tRNAs (primary sequence of this tRNA includes 29A, 24U, 11C and 7G residues).
Post-transcriptional modifications restrict the 2D folding space to a single cloverleaf
Human mt-tRNAAsp presents four post-transcriptional modifications, namely m1A9, m2G10, Ψ27 and Q34. Some of these modifications are only present partially, i.e. all copies of the tRNA are not modified at all positions, suggesting the existence of several ‘modivariants’ (54), as already observed for other human mt-tRNAs (20). m1A9 is typical for mt-tRNAs and is very rare in other tRNAs (2,55). As discussed above, an unprecedented structural role for this modification was revealed along studies of human mt-tRNALys where the methyl group hinders Watson–Crick base-pairing of residue 9 with residue 64 (in the T-stem) and thus hinders folding of the RNA into an extended hairpin (24,45). m1A9 was also shown to be crucial for structure and function of nematode mt-tRNAs lacking the entire T-arm (56). If this methyl group is inserted by the newly discovered methylase activity of human mt-RNase P (57) remains an open question. m2G10 is a frequent modification in many tRNA families, which does not hinder Watson–Crick interaction (2,55). Ψ27 is present in about 20% of all tRNAs and stabilizes the base-pairing with A43 (58) and is present in many mt-tRNAs (2,55). The contribution of Ψ27 to mt-tRNA stability has been explicitly demonstrated for bovine mt-tRNAMet (59). Interestingly also, the absence of Ψ27 and Ψ28 in human cytosolic and mt-tRNAs has been correlated to sideroblastic anemiae due to an inactive pseudouridine synthase (60). Finally, Q34 is a G modification present in the anticodon loop of eukaryal and bacterial tRNAs (2,55). It is also present in a few mt-tRNAs from which tRNAAsp from Asterias amurensis, Didelphis virginiana and Rattus norvegicus. We report here its first description in a human mt-tRNA. This modification is likely involved in codon reading (61).
The enzymatic and chemical structure probing performed on native, post-transcriptionally modified, human mt-tRNAAsp extracted from HeLa cells reveals a perfect fit between nucleotide reactivities and a cloverleaf 2D folding (Figure 3). These data, different from those found for the corresponding in vitro transcript, illustrate the role of the post-transcriptional modifications in the achievement of functional tRNAAsp molecules in human mitochondria. Contribution of post-transcriptional modifications to tRNA folding and stability is well established with examples in different kingdoms of life and in mt-tRNAs (62–64).
Classical tertiary interactions in the core but not in D/T loop interactions, define the 3D structure of native mt-tRNAAsp
Secondary elements of native human mt-tRNAAsp appear well defined. The predicted stems (acceptor arm, D-, anticodon and T-stems) are reactive to double-strand specific enzymatic probe and non reactive to chemical probes. The predicted loops react in an opposite way, i.e. strong cleavages by the single-strand specific enzymatic probe and high reactivity toward chemical probes. Two main domains of the potential 3D structure have to be considered in regard to tertiary interactions. D- and T-loop nucleotides are strongly reactive to probes, not in support of interactions between these loops. However, the reactivity of some nucleotides from both loops fits with a possible role in the tertiary network, according to rules established for classical tRNAs. Reactivities are compatible for the following interactions: A14–U8, A21–A14 and A58–C54 (or A58–U55). Reactivities of residues within the variable domain and of residue 26 are compatible with the following triples: G10–C25/A45, A13–U12/A46 and A26–A44. The existence of triple 9/12–23 has been previously supported experimentally, combining a structural and functional mutagenic approach (33). Only interaction between residues 15 and 48 could not be tested (reactivity of residue 15 is poisoned by a systematic degradation of the 15–16 phosphodiester bond and U48 is not sensitive to the probes used herein).
In summary, chemical and enzymatic probing performed herein is concordant with probing performed on classical tRNAs (65) and can be interpreted by at least five out of the six expected tertiary interactions taking place in the core domain of the tRNA, involving the D-domain and the variable region. These findings are strengthened by compilation of 136 mammalian mt-tRNAAsp sequences, which revealed a high conservation in nucleotides within the core domain of the tRNA (see Supplementary Data). Moreover, more than 98% of nucleotide combinations in the full set of 16 nt involved in the six core interactions are compatible with conservation of Leontis–Westhof interaction types (Table 2). Accordingly, the six tertiary interactions can exist and are conserved in mammalian mt-tRNAAsp. A 3D graphics model of human mt-tRNAAsp has been built accordingly, on the basis of the crystallographic structure of E. coli tRNAAsp in complex with the cognate aspartyl-tRNA synthetase (27). Figure 5 presents the model and highlights the predicted interactions in the core of the molecule. It also illustrates the main absence of interactions between the D- and T-loops.
Evolution of mammalian mt-tRNA structures
Mammalian mt-tRNAs are considered as ‘bizarre’ tRNAs due to skewed nucleotide composition and to important size and sequence variations in the D- and T-loops. Here we show that the 3D structure of human mt-tRNAAsp is based on a core domain made up of the classical set of six tertiary interactions. This tRNA presents also a restricted set of four post-transcriptional modifications, all of classical type, from which m1A9, m2G10, Ψ27 stabilize the fold. The L-shaped structure remains unusual in regard to its elbow for which no interactions between the D- and T-loops could be detected. However, neither the contribution of residue 60 in the T-loop nor that of specific magnesium ions (59) could be evaluated. Rules determined for human mt-tRNAAsp can be extended to 136 mammalian mt-tRNAs of the same specificity. Detailed structural properties of 19 mammalian mt-tRNA families of different specificities need to be explored to verify if the observations established herein for tRNAAsp can be generalized, or if on the contrary some tRNAs present alternative tertiary networks. We recall that serine specific tRNAs do possess alternate networks (8–10). The recent crystal structure of pyrrolysine specific tRNA from Desulfitobacterium hafniense features unprecedented tertiary interactions (66). These are likely valid for the mt-tRNASer(UCN) which shares very similar typical secondary structure characteristics (8,9).
The size and sequence degeneracy observed for mammalian mt-tRNA D- and T-loops parallels the functional degeneracy observed for aminoacylation identity sets, restricted in number as compared to other tRNAs (14,67,68). Interestingly, local mutation of aspartyl-tRNA synthetase in response to the loss of the major identity element G73 is an explicit demonstration of an adaptation in a complementary partnership (14). More generally, it is observed that mt-DNA encoded RNA degeneracy is compensated for by adaptation of partner macromolecules belonging to the translational machinery. An extended elongation factor exists specifically for the D-stem deprived tRNASer(AGY) (69), a highly protein rich mitochondrial ribosome compensates for restricted 12S and 16S rRNA sequences coded by the mt genome (70) and finally, RNaseP is deprived of an RNA moiety but enriched in protein subunits (57).
Mammalian mt-tRNA structures remain to be defined during interaction with e.g. post-transcriptional modification enzymes, cognate aminoacyl-tRNA synthetases and mito-ribosomal A, P and E-sites. Large plasticity of tRNA structures is required for each of these partnerships when classical tRNAs are considered, as for example with aminoacyl-tRNA synthetases (e.g. 71), tRNA-guanine transglycosylase (72), or during interaction with the ribosome (73,74). Structural knowledge on mammalian mt-tRNAs will also allow for better understanding of the molecular impacts of mutations correlated with neurodegenerative disorders (43,75).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg, Association Française contre les Myopathies, Action Concertée Incitative (ACI BCMS) (to C.F.); the Ministry of Education, Science, Sports, and Culture of Japan (to Tom,S.); a JSPS Fellowship for Japanese Junior Scientists (to Takeo,S.); the New Energy and Industrial Technology Development Organization (NEDO) (to Tom,S.); and a fellowship from Ministère de l’Enseignement Supérieur et de la Recherche (to M.M.). Funding for open access charge: CNRS, Université de Strasbourg, AFM.
Conflict of interest statement. None declared.
Supplementary Material
ACKNOWLEDGEMENTS
We thank Joëlle Rudinger-Thirion for helpful advice, Richard Giegé for constructive comments on the manuscript and Louis Levinger for english language improvements. We are grateful to Yohei Kirino (University of Pennsylvania) and Yuriko Sakaguchi (University of Tokyo) for providing materials and technical assistance.
REFERENCES
- 1.Giegé R. Toward a more complete view of tRNA biology. Nat. Struct. Mol. Biol. 2008;15:1007–1014. doi: 10.1038/nsmb.1498. [DOI] [PubMed] [Google Scholar]
- 2.Jühling F, Mörl M, Hartmann RK, Sprinzl M, Stadler PF, Pütz J. tRNAdb 2009: compilation of tRNA sequences and tRNA genes. Nucleic Acids Res. 2009;37:D159–D162. doi: 10.1093/nar/gkn772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kim SH, Suddath FL, Quigley GJ, McPherson A, Sussman JL, Wang AHJ, Seeman NC, Rich A. Three dimensional tertiary structure of yeast phenylalanine transfer RNA. Science. 1974;185:435–440. doi: 10.1126/science.185.4149.435. [DOI] [PubMed] [Google Scholar]
- 4.Robertus JD, Ladner JE, Finch JT, Rhodes D, Brown RS, Clarck BFC, Klug A. Correlation between three-dimensional structure and chemical reactivity of transfer RNA. Nucleic Acids Res. 1974;1:927–932. doi: 10.1093/nar/1.7.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Giegé R, Puglisi JD, Florentz C. tRNA structure and aminoacylation efficiency. Prog. Nucleic Acid Res. Mol. Biol. 1993;45:129–206. doi: 10.1016/s0079-6603(08)60869-7. [DOI] [PubMed] [Google Scholar]
- 6.Dirheimer G, Keith G, Dumas P, Westhof E. In: tRNA: Structure, Biosynthesis, and Function. Söll D, RajBhandary UL, editors. Washington DC: American Society for Microbiology Press; 1995. pp. 93–126. [Google Scholar]
- 7.Helm M, Brulé H, Friede D, Giegé R, Pütz J, Florentz C. Search for characteristic structural features of mammalian mitochondrial tRNAs. RNA. 2000;6:1356–1379. doi: 10.1017/s1355838200001047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Yokogawa T, Watanabe Y, Kumazawa Y, Ueda T, Hirao I, Miura K, Watanabe K. A novel cloverleaf structure found in mammalian mitochondrial tRNASer(UCN) Nucleic Acids Res. 1991;19:6101–6105. doi: 10.1093/nar/19.22.6101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hayashi I, Kawai G, Watanabe K. Higher-order structure and thermal instability of bovine mitochondrial tRNAUGASer investigated by proton NMR spectroscopy. J. Mol. Biol. 1998;284:57–69. doi: 10.1006/jmbi.1998.2151. [DOI] [PubMed] [Google Scholar]
- 10.Hayashi I, Yokogawa T, Kawai G, Ueda T, Nishikawa K, Watanabe K. Assignment of imino proton signals of G-C base pairs and magnesium ion binding: an NMR study of bovine mitochondrial tRNAGCUSer lacking the entire D arm. J. Biochem. 1997;121:1115–1122. doi: 10.1093/oxfordjournals.jbchem.a021703. [DOI] [PubMed] [Google Scholar]
- 11.Leehey MA, Squassoni CA, Friederich MW, Mills JB, Hagerman PJ. A noncanonical tertiary conformation of a human mitochondrial transfer RNA. Biochemistry. 1995;34:16235–16239. doi: 10.1021/bi00050a001. [DOI] [PubMed] [Google Scholar]
- 12.Frazer-Abel AA, Hagerman PJ. Determination of the angle between the acceptor and anticodon stems of a truncated mitochondrial tRNA. J. Mol. Biol. 1999;285:581–593. doi: 10.1006/jmbi.1998.2320. [DOI] [PubMed] [Google Scholar]
- 13.Wakita K, Watanabe YI, Yokogawa T, Kumazawa Y, Nakamura S, Ueda T, Watanabe K, Nishikawa K. Higher-order structure of bovine mitochondrial tRNAPhe lacking the ‘conserved’ GG and TΨCG sequences as inferred by enzymatic and chemical probing. Nucleic Acids Res. 1994;22:347–353. doi: 10.1093/nar/22.3.347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Fender A, Sauter C, Messmer M, Pütz J, Giegé R, Florentz C, Sissler M. Loss of a primordial identity element for a mammalian mitochondrial aminoacylation system. J. Biol. Chem. 2006;281:15980–15986. doi: 10.1074/jbc.M511633200. [DOI] [PubMed] [Google Scholar]
- 15.Kirino Y, Yasukawa T, Ohta S, Akira S, Ishihara K, Watanabe K, Suzuki T. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc. Natl Acad. Sci. USA. 2004;101:15070–15075. doi: 10.1073/pnas.0405173101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Suzuki T, Suzuki T. Chaplet column chromatography: isolation of a large set of individual RNAs in a single step. Methods Enzymol. 2007;425:231–239. doi: 10.1016/S0076-6879(07)25010-4. [DOI] [PubMed] [Google Scholar]
- 17.Suzuki T, Ikeuchi Y, Noma A, Suzuki T, Sakaguchi Y. Mass spectrometric identification and characterization of RNA-modifying enzymes. Methods Enzymol. 2007;425:211–229. doi: 10.1016/S0076-6879(07)25009-8. [DOI] [PubMed] [Google Scholar]
- 18.Mengel-Jørgensen J, Kirpekar F. Detection of pseudouridine and other modifications in tRNA by cyanoethylation and MALDI mass spectrometry. Nucleic Acids Res. 2002;30:e135. doi: 10.1093/nar/gnf135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Yokogawa T, Kumazawa Y, Miura K-I, Watanabe K. Purification and characterization of two serine isoacceptor tRNAs from bovine mitochondria by using a hybridization assay method. Nucleic Acids Res. 1989;17:2623–2638. doi: 10.1093/nar/17.7.2623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Helm M, Florentz C, Chomyn A, Attardi G. Search for differences in post-transcriptional modification patterns of mitochondrial DNA-encoded wild-type and mutant human tRNALys and tRNALeu(UUR) Nucleic Acids Res. 1999;27:756–763. doi: 10.1093/nar/27.3.756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bonnefond L, Fender A, Rudinger-Thirion J, Giegé R, Florentz C, Sissler M. Towards the full set of human mitochondrial aminoacyl-tRNA synthetases: characterization of AspRS and TyrRS. Biochemistry. 2005;44:4805–4816. doi: 10.1021/bi047527z. [DOI] [PubMed] [Google Scholar]
- 22.Fechter P, Rudinger J, Giegé R, Théobald-Dietrich A. Ribozyme processed tRNA transcripts with unfriendly internal promoter for T7 RNA polymerase: production and activity. FEBS Lett. 1998;436:99–103. doi: 10.1016/s0014-5793(98)01096-5. [DOI] [PubMed] [Google Scholar]
- 23.Becker HD, Giegé R, Kern D. Identity of prokaryotic and eukaryotic tRNAAsp for aminoacylation by aspartyl-tRNA synthetase from Thermus thermophilus. Biochemistry. 1996;35:7447–7458. doi: 10.1021/bi9601058. [DOI] [PubMed] [Google Scholar]
- 24.Helm M, Brulé H, Degoul F, Cepanec C, Leroux JP, Giegé R, Florentz C. The presence of modified nucleotides is required for cloverleaf folding of a human mitochondrial tRNA. Nucleic Acids Res. 1998;26:1636–1643. doi: 10.1093/nar/26.7.1636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Peattie DA, Gilbert W. Chemical probes for higher-order structure in RNA. Proc. Natl Acad. Sci. USA. 1980;77:4679–4682. doi: 10.1073/pnas.77.8.4679. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bonnefond L, Florentz C, Giegé R, Rudinger-Thirion J. Decreased aminoacylation in pathology-related mutants of mitochondrial tRNATyr is associated with structural perturbations in tRNA architecture. RNA. 2008;14:641–648. doi: 10.1261/rna.938108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Eiler S, Dock-Bregeon AC, Moulinier L, Thierry JC, Moras D. Synthesis of aspartyl-tRNAAsp in Escherichia coli-a snapshot of the second step. EMBO J. 1999;18:6532–6541. doi: 10.1093/emboj/18.22.6532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kleywegt GJ, Zou JY, Kjeldgaard M, Jones TA. In: International Tables for Crystallography. Rossmann MG, Arnold E, editors. Chapter 17.11. Kluwer Academic, Dordrecht (The Netherlands: F. Crystallography of Biological Macromolecules; 2001. pp. 353–356. 366–367. [Google Scholar]
- 29.Jossinet F, Westhof E. Sequence to Structure (S2S): display, manipulate and interconnect RNA data from sequence to structure. Bioinformatics. 2005;21:3320–3321. doi: 10.1093/bioinformatics/bti504. [DOI] [PubMed] [Google Scholar]
- 30.Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Cryst. 1998;D54:905–921. doi: 10.1107/s0907444998003254. [DOI] [PubMed] [Google Scholar]
- 31.DeLano WL. San Carlos, CA, USA: Delano Scientific; 2002. Delano Scientific. http://www.pymol.org. [Google Scholar]
- 32.Pütz J, Dupuis B, Sissler M, Florentz C. Mamit-tRNA, a database of mammalian mitochondrial tRNA primary and secondary structures. RNA. 2007;13:1184–1190. doi: 10.1261/rna.588407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Messmer M, Gaudry A, Sissler M, Florentz C. Pathology-related mutation A7526G (A9G) helps in the understanding of the 3D structural core of human mitochondrial tRNAAsp. RNA. 2009;15:1462–1468. doi: 10.1261/rna.1626109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Chen EY, Roe BA. Structural comparison of human, bovine, rat, and Walker 256 carcinosarcoma asparaginyl-tRNA. Biochim. Biophys. Acta. 1980;610:272–284. doi: 10.1016/0005-2787(80)90009-x. [DOI] [PubMed] [Google Scholar]
- 35.Ehresmann C, Baudin F, Mougel M, Romby P, Ebel JP, Ehresmann B. Probing the structure of RNAs in solution. Nucleic Acids Res. 1987;15:9109–9128. doi: 10.1093/nar/15.22.9109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Giegé R, Helm M, Florentz C. In: Prebiotic Chemistry, Molecular Fossils, Nucleosides, and RNA, Vol. 6. Söll D, Nishimura S, Moore P, editors. Oxford: Pergamon; 1999. pp. 63–80. [Google Scholar]
- 37.Brunel C, Romby P. Probing RNA structure and RNA–ligand complexes with chemical probes. Methods Enzymol. 2000;318:3–21. doi: 10.1016/s0076-6879(00)18040-1. [DOI] [PubMed] [Google Scholar]
- 38.Sohm B, Frugier M, Brulé H, Olszak K, Przykorska A, Florentz C. Towards understanding human mitochondrial leucine aminoacylation identity. J. Mol. Biol. 2003;328:995–1010. doi: 10.1016/s0022-2836(03)00373-5. [DOI] [PubMed] [Google Scholar]
- 39.Steinberg S, Cedergren R. Structural compensation in atypical mitochondrial tRNAs. Nature Struct. Biol. 1994;1:507–510. doi: 10.1038/nsb0894-507. [DOI] [PubMed] [Google Scholar]
- 40.Steinberg S, Gautheret D, Cedergren R. Fitting the structurally diverse animal mitochondrial tRNAsSer to common three-dimensional constraints. J. Mol. Biol. 1994;236:982–989. doi: 10.1016/0022-2836(94)90004-3. [DOI] [PubMed] [Google Scholar]
- 41.Steinberg S, Leclerc F, Cedergren R. Structural rules and conformational compensations in the tRNA L-form. J. Mol. Biol. 1997;266:269–282. doi: 10.1006/jmbi.1996.0803. [DOI] [PubMed] [Google Scholar]
- 42.Leontis NB, Stombaugh J, Westhof E. The non-Watson-Crick base pairs and their associated isostericity matrices. Nucleic Acids Res. 2002;30:3497–3531. doi: 10.1093/nar/gkf481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Florentz C, Sohm B, Tryoen-Tóth P, Pütz J, Sissler M. Human mitochondrial tRNAs in health and disease. Cell Mol. Life Sci. 2003;60:1356–1375. doi: 10.1007/s00018-003-2343-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Levinger L, Mörl M, Florentz C. Mitochondrial tRNA 3' end metabolism and human disease. Nucleic Acids Res. 2004;32:5430–5441. doi: 10.1093/nar/gkh884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Helm M, Giegé R, Florentz C. A Watson-Crick base-pair disrupting methyl group (m1A9) is sufficient for cloverleaf folding of human mitochondrial tRNALys. Biochemistry. 1999;38:13338–13346. doi: 10.1021/bi991061g. [DOI] [PubMed] [Google Scholar]
- 46.Sissler M, Helm M, Frugier M, Giegé R, Florentz C. Aminoacylation properties of pathology-related variants of human mitochondrial tRNALys variants. RNA. 2004;10:841–853. doi: 10.1261/rna.5267604. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Voigts-Hoffmann F, Hengesbach M, Kobitski AY, van Aerschot A, Herdewijn P, Nienhaus GU, Helm M. A methyl group controls conformational equilibrium in human mitochondrial tRNALys. J. Am. Chem. Soc. 2007;129:13382–13383. doi: 10.1021/ja075520+. [DOI] [PubMed] [Google Scholar]
- 48.Kobitski AY, Hengesbach M, Helm M, Niehaus GU. Sculpting an RNA conformational energy landscape by a methyl group modification – a single -molecule FRET study. Angew. Chem. Int. Ed. Engl. 2008;47:4326–4330. doi: 10.1002/anie.200705675. [DOI] [PubMed] [Google Scholar]
- 49.Levinger L, Giegé R, Florentz C. Pathology-related substitutions in human mitochondrial tRNAIle reduce precursor 3′-end processing efficiency in vitro. Nucleic Acids Res. 2003;31:1904–1912. doi: 10.1093/nar/gkg282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wittenhagen LM, Roy MD, Kelley SO. The pathogenic U3271C human mitochondrial tRNALeu(UUR) mutation disrupts a fragile anticodon stem. Nucleic Acid Res. 2003;31:596–601. doi: 10.1093/nar/gkg131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Roy MD, Wittenhagen LM, Kelley SO. Structural probing of a pathogenic tRNA dimer. RNA. 2005;11:254–260. doi: 10.1261/rna.7143305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Sohm B, Sissler M, Park H, King MP, Florentz C. Recognition of human mitochondrial tRNALeu(UUR) by its cognate leucyl-tRNA synthetase. J. Mol. Biol. 2004;339:17–29. doi: 10.1016/j.jmb.2004.03.066. [DOI] [PubMed] [Google Scholar]
- 53.Anderson S, Bankier AT, Barrel BG, de Bruijn MHL, Coulson AR, Drouin J, Eperon JC, Nierlich DP, Roe BA, Sanger F, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457–465. doi: 10.1038/290457a0. [DOI] [PubMed] [Google Scholar]
- 54.Madore E, Florentz C, Giegé R, Sekine Si, Yokoyama S, Lapointe J. Effect of modified nucleotides on Escherichia coli tRNAGlu structure and on its aminoacylation by glutamyl-tRNA synthetase; predominant and distinct roles of the mnm5 and s2 modifications of U34. Eur. J. Biochem. 1999;266:1128–1135. doi: 10.1046/j.1432-1327.1999.00965.x. [DOI] [PubMed] [Google Scholar]
- 55.Grosjean H. In: DNA and RNA Modification Enzymes: Structure, Mechanisms, Functions and Evolution, Vol. 1. Grosjean H, editor. USA: Landes BioScience; 2009. pp. 1–18. [Google Scholar]
- 56.Sakurai M, Ohtsuki T, Watanabe K. Modification at position 9 with 1-methyladenosine is crucial for structure and function of nematode mitochondrial tRNAs lacking the entire T-arm. Nucleic Acids Res. 2005;33:1653–1661. doi: 10.1093/nar/gki309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Holzmann J, Frank P, Loffler E, Bennett KL, Gerner C, Rossmanith W. RNaseP without RNA: identification and functional reconstitution of the human mitochondrial tRNA processing enzyme. Cell. 2008;135:462–474. doi: 10.1016/j.cell.2008.09.013. [DOI] [PubMed] [Google Scholar]
- 58.Auffinger P, Westhof E. In: Modification and Editing of RNA. Grosjean H, Benne R, editors. Washington: ASM Press; 1998. pp. 103–112. [Google Scholar]
- 59.Jones CI, Spencer AC, Hsu JL, Spremulli LL, Martinis SA, DeRider M, Agris PF. A counterintuitive Mg2+-dependent and modification-assisted functional folding of mitochondrial tRNAs. J. Mol. Biol. 2006;362:771–786. doi: 10.1016/j.jmb.2006.07.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA) Am. J. Hum. Genet. 2004;74:1303–1308. doi: 10.1086/421530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Yokoyama S, Nishimura S. In: tRNA: Structure, Biosynthesis, and Function. Söll D, RajBhandary U, editors. Washington DC: ASM; 1995. pp. 207–223. [Google Scholar]
- 62.Gustilo EM, Vendeix FA, Agris PF. tRNA's; modifications bring order to gene expression. Curr Opin Microbiol. 2008;11:134–140. doi: 10.1016/j.mib.2008.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Grosjean H. DNA and RNA Modification Enzymes: Structure, Mechanisms, Functions and Evolution. USA: Landes BioScience; 2009. [Google Scholar]
- 64.Hayrapetyan A, Seidu-Larry S, Helm M. In: DNA and RNA Modification Enzymes: Comparative Structure, Mechanism, Functions, Cellular Interactions and Evolution, chapter 37. Grosjean H, editor. USA: Landes BioSciences; 2009. [Google Scholar]
- 65.Romby P, Moras D, Dumas P, Ebel JP, Giegé R. Comparison of the tertiary structure of yeast tRNAAsp and tRNAPhe in solution. Chemical modification study of the bases. J. Mol. Biol. 1987;195:193–204. doi: 10.1016/0022-2836(87)90336-6. [DOI] [PubMed] [Google Scholar]
- 66.Nozawa K, O'D;onoghue P, Gundllapalli S, Araiso Y, Ishitani R, Umehara T, Soll D, Nureki O. Pyrrolysyl-tRNA synthetase-tRNA(Pyl) structure reveals the molecular basis of orthogonality. Nature. 2009;457:1163–1167. doi: 10.1038/nature07611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Lenhard B, Orellana O, Ibba M, Weygand-Durasevic I. tRNA recognition and evolution of determinants in seryl-tRNA synthesis. Nucleic Acids Res. 1999;27:721–729. doi: 10.1093/nar/27.3.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Bonnefond L, Frugier M, Giegé R, Rudinger-Thirion J. Human mitochondrial TyrRS disobeys the tyrosine idenity rules. RNA. 2005;11:558–562. doi: 10.1261/rna.7246805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Ohtsuki T, Sato A, Watanabe YI, Watanabe K. A unique serine-specific elongation factor Tu found in nematode mitochondria. Nat. Struct. Biol. 2002;9:669–673. doi: 10.1038/nsb826. [DOI] [PubMed] [Google Scholar]
- 70.Sharma MR, Koc EC, Datta PP, Booth TM, Spremulli LL, Agrawal RK. Structure of the mammalian mitochondrial ribosome reveals an expanded functional role for its component proteins. Cell. 2003;115:97–108. doi: 10.1016/s0092-8674(03)00762-1. [DOI] [PubMed] [Google Scholar]
- 71.Ruff M, Krishnaswamy S, Boeglin M, Poterszman A, Mitschler A, Podjarny A, Rees B, Thierry JC, Moras D. Class II aminoacyl transfer RNA synthetases: crystal structure of yeast aspartyl-tRNA synthetase complexed with tRNAAsp. Science. 1991;252:1682–1689. doi: 10.1126/science.2047877. [DOI] [PubMed] [Google Scholar]
- 72.Ishitani R, Nureki O, Nameki N, Okada N, Nishimura S, Yokoyama S. Alternative tertiary structure of tRNA for recognition by a posttranscriptional modification enzyme. Cell. 2003;113:383–394. doi: 10.1016/s0092-8674(03)00280-0. [DOI] [PubMed] [Google Scholar]
- 73.Yusupov MM, Yusupova GZ, Baucom A, Lieberman K, Earnest TN, Cate JHD, Noller HF. Crystal structure of the ribosome at 5.5Å resolution. Science. 2001;292:883–896. doi: 10.1126/science.1060089. [DOI] [PubMed] [Google Scholar]
- 74.Selmer M, Dunham CM, Murphy FV, IV, Weixlbaumer A, Petry S, Kelley AC, Weir JR, Ramakrishnan V. Structure of the 70S ribosome complexed with mRNA and tRNA. Science. 2006;313:1935–1942. doi: 10.1126/science.1131127. [DOI] [PubMed] [Google Scholar]
- 75.Wittenhagen LM, Kelley SO. Impact of disease-related mitochondrial mutations on tRNA structure and function. TIBS. 2003;28:605–611. doi: 10.1016/j.tibs.2003.09.006. [DOI] [PubMed] [Google Scholar]
- 76.Mcluckey SA, Vanberkel GJ, Glish GL. Tandem mass-spectrometry of small, multiply charged oligonucleotides. J. Am. Soc. Mass Spectrometry. 1992;3:60–70. doi: 10.1016/1044-0305(92)85019-G. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.